GSK And Novartis Double Down On Neglected Disease R&D Spend
Big Pharma Steps Up
Executive Summary
GSK will invest over $1bn over the next decade to develop medicines that combat malaria, neglected tropical diseases and antibiotic resistance, while Novartis is putting in $250m over the next five years.
You may also be interested in...
Bayer Backs Eylea's Prospects Despite Lucentis Biosimilars
Competition, both branded and generic, is on the rise but the German group believes that Eylea will continue to outperform given its safety and efficacy profile and the potential of a longer-lasting version of the eye therapy.
Gilead Grabs MiroBio's Checkpoint Agonists For $405m
Just over a month after raising $97m in a series B round, Oxford University spinout MiroBio and its immune checkpoint agonists have been snapped up by Gilead Sciences.
F2G Tops Up Funds For Launch Of New Class Of Antifungal
Having banked a $100m upfront fee from licensing partner Shionogi a couple of months ago, F2G has now unveiled a $70m financing to advance its late-stage novel oral antifungal, olorofim.